Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ascletis Pharma, Inc. ( (HK:1672) ) has provided an update.
Ascletis Pharma Inc. announced promising results from its U.S. Phase Ib study of the ASC30 oral once-daily tablet, which showed significantly higher drug exposure compared to orforglipron, a competing treatment. This higher exposure is linked to greater weight loss in participants with obesity, positioning ASC30 as a potentially competitive treatment. The study also highlighted ASC30’s favorable safety and tolerability profile, with no serious adverse events reported, suggesting its potential as a differentiated option in the obesity treatment market.
The most recent analyst rating on (HK:1672) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. operates in the pharmaceutical industry, focusing on developing innovative therapies. The company specializes in small molecule drugs and has a market focus on treating obesity with its investigational GLP-1R biased small molecule agonist, ASC30.
Average Trading Volume: 8,231,747
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.01B
Learn more about 1672 stock on TipRanks’ Stock Analysis page.